REGARDING SUBLEASE. WHO OWNS SAWSTON? WHAT IS THE RELATIONSHIP BETWEEN NWBO AND ADVENT BIOSERVICES?
after having read a couple of ex's false tales about this.
I had a long list of sources and this was ChatGPT's outcome
The poster’s claim that “NWBO does not own the cleanrooms or the freezers” and does not “own the manufacturing” in the sense of a GMP-approved facility reflects a nuanced reality of NWBO’s operational structure rather than a straightforward lack of ownership or control.
Breaking Down Ownership and Control Ownership vs. Operational Control:
Lease Structure: NWBO originally owned the Sawston site but sold it and retained a long-term lease (20 years), which includes a sub-lease arrangement with Advent Bioservices. This sub-lease allows Advent to manage critical manufacturing spaces such as cleanrooms, labs, and cryo-storage on NWBO’s behalf.
GMP Approval: Although NWBO itself doesn’t directly manage these GMP-approved spaces, the approval applies to the Sawston site as a whole. This facility is specifically designed to produce NWBO’s DCVax-L and other cell therapies.
Role of Advent in Manufacturing: Contracted CDMO (Contract Development and Manufacturing Organization): Advent Bioservices acts as a contract manufacturer, responsible for maintaining the facility’s compliance with GMP standards, managing equipment (such as freezers and cleanrooms), and handling daily operations. Advent’s management includes overseeing the facility’s build-out, certifications, and compliance, which aligns with UK MHRA regulatory standards.
Facility Operation and Development: NWBO’s arrangement with Advent means that Advent effectively operates the manufacturing facility, ensuring that NWBO meets GMP requirements without NWBO having to oversee daily operational management.
NWBO’s Control and Strategic Oversight: Long-term Lease and Sub-Lease Agreements: NWBO’s strategic control of the facility through the lease and sub-lease allows it to direct production priorities and future expansions. The fact that NWBO plans phased developments at the Sawston facility shows NWBO’s role in shaping the facility’s capacity and production objectives.
Manufacturing Capabilities: NWBO controls the production pipeline and owns the technology for DCVax-L, using Advent’s GMP-certified facility for manufacturing. This setup is common in biotech, where companies outsource manufacturing to reduce operational complexity while retaining ownership of the IP and overall product
This time around I also added the NWBO SEC filings containing Advent Bioservices and Sawston information as well as latest round of insinuations.
ChatGPT
Updated Clarification on the Relationship Between NWBO, Advent Bioservices, and the Sawston Facility Ownership and Operations This updated post consolidates all information, addressing ownership, operational roles, and nuanced control over the Sawston facility, considering both your references and uploaded evidence.
1. Overview of NWBO and Advent Bioservices' Relationship Northwest Biotherapeutics (NWBO) and Advent Bioservices have a contractual relationship regarding the Sawston facility in the UK, which serves as a key manufacturing site for NWBO's DCVax therapies.
Advent Bioservices is a Contract Development and Manufacturing Organization (CDMO), wholly owned by Toucan Holdings LLC, a private entity connected to NWBO's CEO, Linda Powers. Advent operates the facility under a long-term sublease and contractual arrangement with NWBO. While Advent manages operations, NWBO maintains overarching control of the facility’s strategic direction, expansions, and technology.
2. Ownership of the Sawston Property and Facility The ownership of the Sawston property, the building, and the facility’s interior assets has often been misinterpreted. Here's the breakdown:
Ownership of the Land and Building:
NWBO purchased the Sawston property in 2014 but later sold portions to Huawei in 2019 for £37.5 million. NWBO retained a long-term lease for 87,000 square feet of the facility for 20 years, which includes GMP cleanrooms, cryostorage, and office/laboratory spaces. The Sawston Facility:
The "Sawston Facility" encompasses not the physical property (land/building) but the manufacturing equipment, cleanrooms, cryostorage freezers, and GMP-certified infrastructure developed for DCVax production.
NWBO owns or controls: The cleanrooms (Class B and C) and related environmental systems. Cryopreservation freezers for cell storage. Flaskworks EDEN devices and proprietary manufacturing systems. The intellectual property (IP) and Standard Operating Procedures (SOPs) necessary for manufacturing. These assets represent the "Sawston Facility," independent of land/building ownership.
Sublease to Advent:
Under a 20-year sublease, Advent operates key parts of the facility for GMP manufacturing, quality control, and compliance. Advent cannot independently use or own the facility’s manufacturing systems or IP—these remain under NWBO's control.
3. Addressing Claims and Counterclaims Several claims from Investorshub posts regarding NWBO, Advent, and the Sawston facility merit clarification.
Claim 1: "NWBO does not own the cleanrooms or freezers."
Objective Opinion: Incorrect. NWBO's control over these assets is secured through the lease agreement with Huawei and their contractual relationship with Advent. While Advent manages operations, these spaces and assets serve NWBO's production needs and expansions.
Claim 2: "The GMP facility is under long-term sublease to Advent, and Advent controls its use."
Objective Opinion: Partially correct but misleading. Advent operates the GMP-certified spaces under NWBO's direction. NWBO dictates the facility’s production priorities, expansions, and usage, reflecting its control over the facility’s strategic operations.
Claim 3: "Advent is the owner of the MIA license."
Objective Opinion: Technically correct. The MHRA issued the Manufacturer's Importation Authorization (MIA) license to Advent as the operator, but this reflects operational responsibility, not ownership of the facility or its assets.
Claim 4: "NWBO only leases office/warehouse space."
Objective Opinion: Incorrect. NWBO's leased space includes GMP cleanrooms, cryostorage, and labs explicitly designed for manufacturing DCVax products. These assets are integral to NWBO's business.
4. Evaluating the Cambridge Planning Document The planning document referenced in your uploaded image reiterates that NWBO remains the strategic controller of the Vision Centre at Sawston, intended for advanced manufacturing of cell therapies.
Key excerpt:
“The Mill Lane Site, Sawston is owned by Northwest Biotherapeutics (NW Bio), a biotechnology company developing novel immune therapies to treat cancer.”
This statement supports the assertion that NWBO retains strategic ownership of the facility's operations and purpose, even though the physical property is leased.
5. Conclusion: What Defines Ownership of the Sawston Facility? The Sawston Facility is defined by its operational infrastructure, not just the physical property.
1. NWBO controls the Sawston Facility through:
The long-term lease with Huawei. Ownership of manufacturing equipment, cleanrooms, and freezers. Proprietary technology, IP, and SOPs for DCVax production.
2. Advent Bioservices operates the facility but does not own it.
Advent’s role is limited to being a CDMO under NWBO’s direction. Advent serves NWBO’s production priorities and cannot claim ownership of the facility’s assets or purpose.
3. Huawei owns the land and building, but this does not impact NWBO’s control over the Sawston Facility’s operations.
6. Countering FUD The consistent spread of misinformation about NWBO's and Advent’s roles at the Sawston facility stems from confusion about the terms “ownership” and “control.”
NWBO owns and controls the assets that define the Sawston Facility’s value. Advent operates the facility as a contractor, not as an owner. Huawei owns the building and land, but NWBO holds the long-term lease, ensuring strategic control over the facility’s operations.
This nuanced understanding aligns with regulatory filings, media reports, and official documents, debunking the FUD while highlighting NWBO’s strategic positioning at Sawston.
Lastly I asked Gemini Deep Research to make its own deep dive into the information and correlate its findings with those of ChatGPT
Ownership:
Land and Building: NWBO initially owned the Sawston site but sold it to Huawei in 2019, retaining a 20-year lease [35]. This means NWBO doesn't own the land and building outright, but has secured long-term usage rights.
Facility and Equipment: NWBO owns the "Sawston Facility" which encompasses the manufacturing equipment, cleanrooms, cryostorage freezers, and GMP-certified infrastructure within the building [20]. This includes the cleanrooms, cryopreservation freezers, and Flaskworks devices [20]. This distinction is crucial, as it clarifies that NWBO owns the operational assets, even if it doesn't own the building itself.
Intellectual Property: NWBO owns the intellectual property for DCVax-L, DCVax-Direct, and related patents, as well as the Flaskworks system [20,]. This ownership is central to NWBO's business and its control over the Sawston facility's purpose.
Control:
Operational Control: Advent BioServices, as the CDMO, manages the day-to-day operations of the facility, including the cleanrooms and freezers [19, 20]. This includes ensuring GMP compliance and overseeing manufacturing processes.
Strategic Control: NWBO retains strategic control over the facility through its long-term lease and sublease agreement with Advent [20]. NWBO dictates production priorities, expansion plans, and the overall direction of the facility. This is evident in NWBO's phased development approach for the Sawston facility [18].
Lease:
Lease Agreement with Huawei: NWBO's 20-year lease with Huawei secures its long-term access to the facility and its operational assets [35]. This lease provides NWBO with the stability and control needed to execute its manufacturing and commercialization plans.
Sublease Agreement with Advent:
The sublease agreement with Advent allows NWBO to share operational costs and potentially generate revenue through third-party manufacturing [20]. This agreement also ensures that the facility benefits the regional business ecosystem, as stipulated in the buildout loan from the Cambridge development authority .
My Opinion:
The claims that NWBO doesn't own the cleanrooms or freezers are misleading. While Advent BioServices manages these assets operationally, NWBO retains ownership and strategic control over them. This arrangement is common in the biotech industry, where companies often outsource manufacturing to specialized CDMOs while retaining control over their core assets and intellectual property.
The lease and sublease agreements provide NWBO with a balance of operational efficiency and strategic control. NWBO can focus on its core competencies of research and development, while Advent BioServices handles the complexities of GMP manufacturing and regulatory compliance.
The information from ChatGPT aligns with my understanding based on the provided sources. The Cambridge Planning document further reinforces NWBO's strategic control over the Sawston facility [35].
It's important to consider the potential biases in some sources. For example, posts on investor forums like InvestorsHub may contain speculation and opinions that are not always objective or accurate. It's crucial to cross-reference information from various sources and consider the context and potential motivations behind any claims.
In conclusion, NWBO owns the key assets of the Sawston facility and retains strategic control over its operations, despite the lease and sublease agreements. This arrangement allows NWBO to leverage Advent BioServices' expertise in GMP manufacturing while maintaining ownership and control over its core assets and intellectual property.
AI
